CD73: A potential biomarker for anti-PD-1 therapy

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A(2A) blockade. Since CD73 is known to be overexpressed in several human cancers and A(2A) antagonists have undergone clinical trials for Parkinson's Disease, t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Beavis, Paul A, Slaney, Clare Y, Milenkovski, Nicole, Henderson, Melissa A, Loi, Sherene, Stagg, John, Kershaw, Michael H, Darcy, Phillip K
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Author's View
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589050/
https://ncbi.nlm.nih.gov/pubmed/26451321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046675
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars